Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from a preclinical study of the company’s combination quadrivalent seasonal flu vaccine (NanoFlu™) and COVID-19 vaccine candidate (NVX-CoV2373). The NanoFlu/NVX-CoV2373 combination vaccine demonstrated positive immune responses to both influenza and SARS-CoV-2. A pre-print of the manuscript is available at bioRxiv.org.
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine GAITHERSBURG, Md., May 3, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today [….]
Novavax is aiming to seek Emergency Use Authorization for its COVID-19 vaccine NVX-CoV2373 later this spring. If the U.S. Food and Drug Administration gives it the green light, the Maryland-based company could see revenue of approximately $1.8 billion in sales by the end of the year.
Novavax COVID-19 Vaccine: How Does It Work? In the battle against Covid-19, more than 330 million vaccines have been given out. But a new vaccine candidate is about to enter the arena. [….]
Novavax Plan Outlines Expansion of Gaithersburg Corporate Campus Company says it could add 400 jobs within four years The biotechnology company Novavax, which is at the forefront of the COVID-19 [….]
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. GSK and Novavax will negotiate a final agreement to include additional terms and conditions.
Novavax trials highlight Maryland’s COVID-fighting complex When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers [….]
Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials – 100% protection against severe disease – Final analysis in U.K. trial confirms 96% efficacy [….]
The BioHealth Capital Region (BHCR) had a remarkable 2020, and there is palpable momentum and excitement in the air as we approach the end of Q1 2021. How will the pandemic impact the region’s push to be “Top 3 by 2023?” Where will this significant momentum lead? These questions are yet to be answered.
